Suppr超能文献

JunD和JunB整合前列腺素E2对乳腺癌相关近端芳香化酶启动子的激活作用。

JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters.

作者信息

Chen Dong, Reierstad Scott, Fang Feng, Bulun Serdar E

机构信息

Division of Reproductive Biology Research, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.

出版信息

Mol Endocrinol. 2011 May;25(5):767-75. doi: 10.1210/me.2010-0368. Epub 2011 Mar 10.

Abstract

Aromatase is the key enzyme in estrogen biosynthesis. Normal breast adipose tissue expresses low levels of aromatase via the distal promoter I.4. Breast adipose tissue surrounding a tumor exhibits excessive aromatase expression controlled by proximal aromatase promoters I.3/II, leading to high local levels of estrogen and breast cancer progression. Prostaglandin E(2) (PGE(2)) secreted by malignant breast epithelial cells activates breast cancer-associated aromatase promoters I.3/II, but silences promoter I.4, in cultured human breast adipose fibroblasts (BAF). The c-Jun N-terminal kinase 1 and p38α mitogen activated protein kinases are necessary for PGE(2) activation of aromatase promoters I.3/II; thus, we examined the roles of downstream targets, c-Jun, JunB, JunD, and activating transcription factor 2, in PGE(2)-mediated regulation of aromatase expression in BAF. PGE(2) induced JunB and JunD protein expression through protein kinase A and protein kinase C, respectively. JunB or JunD knockdown by small interfering RNA markedly reduced PGE(2)-induced total aromatase mRNA level and enzyme activity via promoters I.3/II. JunB knockdown also abrogated JunD expression. JunB stimulated, whereas JunD inhibited, aromatase promoter I.4 activity. Activating transcription factor 2 knockdown did not affect promoter-specific or total aromatase mRNA levels. c-Jun knockdown increased promoter I.4-specific and PGE(2)-induced promoters I.3/II-specific aromatase mRNA levels, leading to enhanced PGE(2)-induced total aromatase mRNA level and enzyme activity. JunD, c-Jun, and JunB bound to a CRE(-211/-199) essential for PGE(2) induction of aromatase promoters I.3/II. Taken together, JunD and c-Jun repress aromatase promoter I.4. JunD mediates, whereas c-Jun modulates, PGE(2) activation of aromatase promoters I.3/II via CRE(-211/-199). JunB also activates aromatase promoters I.3/II by maintaining JunD expression. Targeting JunD may abolish aromatase expression selectively in breast cancer tissue.

摘要

芳香化酶是雌激素生物合成中的关键酶。正常乳腺脂肪组织通过远端启动子I.4表达低水平的芳香化酶。肿瘤周围的乳腺脂肪组织表现出由近端芳香化酶启动子I.3/II控制的过度芳香化酶表达,导致局部高水平的雌激素和乳腺癌进展。恶性乳腺上皮细胞分泌的前列腺素E(2)(PGE(2))在培养的人乳腺脂肪成纤维细胞(BAF)中激活与乳腺癌相关的芳香化酶启动子I.3/II,但使启动子I.4沉默。c-Jun氨基末端激酶1和p38α丝裂原活化蛋白激酶是PGE(2)激活芳香化酶启动子I.3/II所必需的;因此,我们研究了下游靶点c-Jun、JunB、JunD和激活转录因子2在PGE(2)介导的BAF中芳香化酶表达调控中的作用。PGE(2)分别通过蛋白激酶A和蛋白激酶C诱导JunB和JunD蛋白表达。通过小干扰RNA敲低JunB或JunD可显著降低PGE(2)通过启动子I.3/II诱导的总芳香化酶mRNA水平和酶活性。敲低JunB也消除了JunD的表达。JunB刺激而JunD抑制芳香化酶启动子I.4的活性。敲低激活转录因子2不影响启动子特异性或总芳香化酶mRNA水平。敲低c-Jun增加了启动子I.4特异性和PGE(2)诱导的启动子I.3/II特异性芳香化酶mRNA水平,导致PGE(2)诱导的总芳香化酶mRNA水平和酶活性增强。JunD、c-Jun和JunB与PGE(2)诱导芳香化酶启动子I.3/II所必需的CRE(-211/-199)结合。综上所述,JunD和c-Jun抑制芳香化酶启动子I.4。JunD介导而c-Jun调节PGE(2)通过CRE(-211/-199)对芳香化酶启动子I.3/II的激活。JunB也通过维持JunD的表达来激活芳香化酶启动子I.3/II。靶向JunD可能会选择性地消除乳腺癌组织中的芳香化酶表达。

相似文献

1
JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters.
Mol Endocrinol. 2011 May;25(5):767-75. doi: 10.1210/me.2010-0368. Epub 2011 Mar 10.
5
Regulation of aromatase expression in breast cancer tissue.
Ann N Y Acad Sci. 2009 Feb;1155:121-31. doi: 10.1111/j.1749-6632.2009.03705.x.
6
8
HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma.
Breast Cancer Res. 2013 Apr 8;15(2):R30. doi: 10.1186/bcr3410.
9
The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):219-24. doi: 10.1016/s0960-0760(03)00359-5.
10
Aromatase activity induction in human adipose fibroblasts by retinoic acids via retinoic acid receptor α.
J Mol Endocrinol. 2013 Sep 10;51(2):247-60. doi: 10.1530/JME-12-0129. Print 2013 Oct.

引用本文的文献

1
Obesity, Diabetes, and Increased Cancer Progression.
Diabetes Metab J. 2021 Nov;45(6):799-812. doi: 10.4093/dmj.2021.0077. Epub 2021 Nov 22.
2
Aromatase expression and regulation in breast and endometrial cancer.
J Mol Endocrinol. 2016 Jul;57(1):R19-33. doi: 10.1530/JME-15-0310. Epub 2016 Apr 11.
3
Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.
Oncologist. 2016 Apr;21(4):404-17. doi: 10.1634/theoncologist.2015-0351. Epub 2016 Feb 10.
5
Quantitative profiling of chromatome dynamics reveals a novel role for HP1BP3 in hypoxia-induced oncogenesis.
Mol Cell Proteomics. 2014 Dec;13(12):3236-49. doi: 10.1074/mcp.M114.038232. Epub 2014 Aug 6.
6
Impact of obesity on mammary gland inflammation and local estrogen production.
J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):183-9. doi: 10.1007/s10911-014-9321-0. Epub 2014 Jun 17.
7
Glucocorticoid-induction of hypothalamic aromatase via its brain-specific promoter.
Mol Cell Endocrinol. 2012 Oct 15;362(1-2):85-90. doi: 10.1016/j.mce.2012.05.012. Epub 2012 Jun 13.
8
Weight gain increases human aromatase expression in mammary gland.
Mol Cell Endocrinol. 2012 May 15;355(1):114-20. doi: 10.1016/j.mce.2012.01.027. Epub 2012 Feb 10.
9
Aromatase, breast cancer and obesity: a complex interaction.
Trends Endocrinol Metab. 2012 Feb;23(2):83-9. doi: 10.1016/j.tem.2011.10.003. Epub 2011 Dec 12.

本文引用的文献

2
Regulation of breast cancer-associated aromatase promoters.
Cancer Lett. 2009 Jan 8;273(1):15-27. doi: 10.1016/j.canlet.2008.05.038. Epub 2008 Jul 9.
3
Characterisation of aromatase expression in the human adipocyte cell line SGBS.
Breast Cancer Res Treat. 2008 Dec;112(3):429-35. doi: 10.1007/s10549-007-9883-2. Epub 2008 Jan 5.
5
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Steroids. 2007 Jan;72(1):7-25. doi: 10.1016/j.steroids.2006.10.009. Epub 2006 Dec 13.
6
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.
Microbiol Mol Biol Rev. 2006 Dec;70(4):1061-95. doi: 10.1128/MMBR.00025-06.
9
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
Curr Opin Oncol. 2005 Nov;17(6):559-65. doi: 10.1097/01.cco.0000180434.31991.bf.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验